NCT02227368View on ClinicalTrials.gov

Walking Effect of Long Term Ticagrelor in Subjects With PAD Who Have Undergone EVR

PHASE2TerminatedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

October 20, 2014

Primary Completion Date

May 23, 2016

Study Completion Date

May 23, 2016

Conditions
Peripheral Artery Disease (PAD)
Interventions
DRUG

Ticagrelor

Antiplatelet therapy approved for ACS. Antagonist of P2Y12 and inhibitor of adenosine diphosphate (ADP)-induced platelet aggregation.

DRUG

Comparator

Aspirin monotherapy anti-platelet treatment for PAD patients following EVR procedures

Trial Locations (10)

10001

Research Site, New York

10701

Research Site, Yonkers

32114

Research Site, Daytona Beach

32216

Research Site, Jacksonville

34239

Research Site, Sarasota

34471

Research Site, Ocala

44195

Research Site, Cleveland

46321

Research Site, Munster

75069

Research Site, McKinney

78229

Research Site, San Antonio

Sponsors

Lead Sponsor

AstraZeneca

Collaborators (1)

CPC Clinical Research
All Listed Sponsors
collaborator

CPC Clinical Research

UNKNOWN

lead

AstraZeneca

INDUSTRY